+

WO1999033982A3 - Human genes and gene expression products i - Google Patents

Human genes and gene expression products i Download PDF

Info

Publication number
WO1999033982A3
WO1999033982A3 PCT/US1998/027610 US9827610W WO9933982A3 WO 1999033982 A3 WO1999033982 A3 WO 1999033982A3 US 9827610 W US9827610 W US 9827610W WO 9933982 A3 WO9933982 A3 WO 9933982A3
Authority
WO
WIPO (PCT)
Prior art keywords
genes
gene expression
expression products
human genes
polynucleotides
Prior art date
Application number
PCT/US1998/027610
Other languages
French (fr)
Other versions
WO1999033982A2 (en
Inventor
Lewis T Williams
Jaime Escobedo
Michael A Innis
Pablo Dominguez Garcia
Julie Sudduth-Klinger
Christoph Reinhard
Klaus Giese
Filippo Randazzo
Giulia C Kennedy
David Pot
Altaf Kassam
George Lamson
Radoje Drmanac
Radomir Crkvenjakov
Mark Dickson
Snezana Drmanac
Ivan Labat
Dena Leshkowitz
David Kita
Veronica Garcia
Lee William Jones
Birgit Stache-Crain
Original Assignee
Chiron Corp
Hyseq Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp, Hyseq Inc filed Critical Chiron Corp
Priority to JP2000526638A priority Critical patent/JP2002500010A/en
Priority to AU20955/99A priority patent/AU2095599A/en
Priority to EP98965500A priority patent/EP1190058A2/en
Publication of WO1999033982A2 publication Critical patent/WO1999033982A2/en
Publication of WO1999033982A3 publication Critical patent/WO1999033982A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

This invention relates to novel human polynucleotides and variants thereof, their encoded polypeptides and variants thereof, to genes corresponding to these polynucleotides and to proteins expressed by the genes. The invention also relates to diagnostic and therapeutic agents employing such novel human polynucleotides, their corresponding genes or gene products, e.g., these genes and proteins, including probes, antisense constructs, and antibodies.
PCT/US1998/027610 1997-12-23 1998-12-22 Human genes and gene expression products i WO1999033982A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2000526638A JP2002500010A (en) 1997-12-23 1998-12-22 Human Genes and Gene Expression Products I
AU20955/99A AU2095599A (en) 1997-12-23 1998-12-25 Human genes and gene expression products i
EP98965500A EP1190058A2 (en) 1997-12-23 1998-12-25 Human genes and gene expression products i

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US6875597P 1997-12-23 1997-12-23
US8066498P 1998-04-03 1998-04-03
US10523498P 1998-10-21 1998-10-21
US10587798P 1998-10-27 1998-10-27
US60/105,877 1998-10-28
US60/105,234 1998-10-28
US21747198A 1998-12-21 1998-12-21
US60/068,755 1998-12-21
US60/080,664 1998-12-21
US09/217,471 1998-12-21

Publications (2)

Publication Number Publication Date
WO1999033982A2 WO1999033982A2 (en) 1999-07-08
WO1999033982A3 true WO1999033982A3 (en) 1999-12-23

Family

ID=27535805

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/027610 WO1999033982A2 (en) 1997-12-23 1998-12-22 Human genes and gene expression products i

Country Status (4)

Country Link
EP (1) EP1190058A2 (en)
JP (1) JP2002500010A (en)
AU (1) AU2095599A (en)
WO (1) WO1999033982A2 (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8999380B2 (en) 2012-04-02 2015-04-07 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
US9107886B2 (en) 2012-04-02 2015-08-18 Moderna Therapeutics, Inc. Modified polynucleotides encoding basic helix-loop-helix family member E41
US9186372B2 (en) 2011-12-16 2015-11-17 Moderna Therapeutics, Inc. Split dose administration
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9334328B2 (en) 2010-10-01 2016-05-10 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US9428535B2 (en) 2011-10-03 2016-08-30 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US9447164B2 (en) 2010-08-06 2016-09-20 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9533047B2 (en) 2011-03-31 2017-01-03 Modernatx, Inc. Delivery and formulation of engineered nucleic acids
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6617438B1 (en) * 1997-11-05 2003-09-09 Sirna Therapeutics, Inc. Oligoribonucleotides with enzymatic activity
US8101349B2 (en) 1997-12-23 2012-01-24 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells and their methods of use II
CA2331886A1 (en) 1998-06-30 2000-01-06 Maria Alexandra Glucksmann 14273 receptor, a g-protein coupled receptor
US6395877B1 (en) 1998-06-30 2002-05-28 Millennium Pharmaceuticals, Inc. 14273 receptor, a novel G-protein coupled receptor
US6448005B1 (en) 1998-06-30 2002-09-10 Millennium Pharmaceuticals, Inc. 14723 Receptor, a novel G-protein coupled receptor
US7534579B2 (en) 1998-06-30 2009-05-19 Millennium Pharmaceuticals, Inc. 14273 receptor, a novel G-protein coupled receptor
AU6263999A (en) * 1998-09-28 2000-04-17 Chiron Corporation Human genes and gene expression products
WO2000044900A2 (en) * 1999-01-29 2000-08-03 Incyte Pharmaceuticals, Inc. Nucleic-acid binding proteins
US7083793B2 (en) 1999-02-26 2006-08-01 Millennium Pharmaceuticals, Inc. Tango 243 polypeptides and uses thereof
AU3382800A (en) * 1999-02-26 2000-09-14 Millennium Pharmaceuticals, Inc. Secreted proteins and uses thereof
US6647341B1 (en) 1999-04-09 2003-11-11 Whitehead Institute For Biomedical Research Methods for classifying samples and ascertaining previously unknown classes
WO2000065067A2 (en) * 1999-04-23 2000-11-02 University Of Washington Prostate-specific polynucleotides, polypeptides and their methods of use
AU6181300A (en) * 1999-07-29 2001-02-19 Helix Research Institute Liver cancer-associated genes
EP1208196B1 (en) 1999-08-03 2006-10-18 Millennium Pharmaceuticals, Inc. 15571, a novel gpcr-like molecule of the secretin-like family and uses thereof
CN1300845A (en) * 1999-12-22 2001-06-27 上海博德基因开发有限公司 Polypeptide-human diaoylglycerol protein kinase subunit 9 and polynucleotide for coding this polypeptide
CA2396127A1 (en) * 1999-12-29 2001-07-12 Torben F. Orntoft Gene expression in biological conditions
DE10004102A1 (en) * 2000-01-31 2002-06-20 Metagen Pharmaceuticals Gmbh Nucleic acids differentially expressed between tumor and normal cells, useful for diagnosis or therapy of tumors and for screening active agents
WO2001059115A2 (en) * 2000-02-09 2001-08-16 Agensys, Inc. 83p5g4: a tissue specific protein highly expressed in prostate cancer
US6627423B2 (en) 2000-03-24 2003-09-30 Millennium Pharmaceuticals, Inc. 21481, a novel dehydrogenase molecule and uses therefor
US6511834B1 (en) 2000-03-24 2003-01-28 Millennium Pharmaceuticals, Inc. 32142,21481,25964,21686, novel human dehydrogenase molecules and uses therefor
EP1268528A2 (en) * 2000-03-28 2003-01-02 Chiron Corporation Human genes and expression products
EP1326985A1 (en) * 2000-08-18 2003-07-16 MERCK PATENT GmbH Identification of a human n-terminal acetyltransferase gene
US7208267B2 (en) 2000-11-22 2007-04-24 Diadexus, Inc. Compositions and methods relating to breast specific genes and proteins
US7601825B2 (en) 2001-03-05 2009-10-13 Agensys, Inc. Nucleic acid and corresponding protein entitled 121P1F1 useful in treatment and detection of cancer
US6924358B2 (en) 2001-03-05 2005-08-02 Agensys, Inc. 121P1F1: a tissue specific protein highly expressed in various cancers
US7927597B2 (en) 2001-04-10 2011-04-19 Agensys, Inc. Methods to inhibit cell growth
AU2002318112B2 (en) 2001-04-10 2007-12-06 Agensys, Inc. Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
DE10118452A1 (en) * 2001-04-12 2002-10-31 Joern Bullerdiek Nucleic acid sequences from hyperplasias and thyroid tumors
JP2005507631A (en) * 2001-08-16 2005-03-24 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング Identification of a novel human N-terminal acetyltransferase
AU2003211696A1 (en) * 2002-03-07 2003-09-16 Bf Research Institute, Inc. p18ABetarP GENE AND p18ABetarP PROTEIN, NOVEL GENE/PROTEIN (p60TRP) INTERACTING THEREWITH TO INHIBIT CELL DEATH AND CELL DEATH PROMOTER
EP1426442A1 (en) * 2002-12-02 2004-06-09 MTM Laboratories AG Marker molecules associated with colorectal lesions
US7306910B2 (en) 2003-04-24 2007-12-11 Veridex, Llc Breast cancer prognostics
EP2578685B1 (en) 2005-08-23 2019-04-17 The Trustees Of The University Of Pennsylvania Rna containing modified nucleosides and methods of use thereof
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
WO2014160243A1 (en) 2013-03-14 2014-10-02 The Trustees Of The University Of Pennsylvania Purification and purity assessment of rna molecules synthesized with modified nucleosides
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
CN105980401A (en) 2013-10-03 2016-09-28 现代治疗公司 Polynucleotides encoding low density lipoprotein receptor
US11007260B2 (en) 2015-07-21 2021-05-18 Modernatx, Inc. Infectious disease vaccines
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
LT3718565T (en) 2015-10-22 2022-06-10 Modernatx, Inc. Respiratory virus vaccines
WO2017070624A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Tropical disease vaccines
WO2017070613A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Human cytomegalovirus vaccine
EP3495494B1 (en) * 2016-08-04 2022-11-30 Shizuoka Prefecture Method for determining presence or absence of risk of developing cancer
WO2018075980A1 (en) 2016-10-21 2018-04-26 Modernatx, Inc. Human cytomegalovirus vaccine
US11103578B2 (en) 2016-12-08 2021-08-31 Modernatx, Inc. Respiratory virus nucleic acid vaccines
WO2018151816A1 (en) 2017-02-16 2018-08-23 Modernatx, Inc. High potency immunogenic compositions
MA50253A (en) 2017-09-14 2020-07-22 Modernatx Inc ZIKA VIRUS RNA VACCINES
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
WO2020190750A1 (en) 2019-03-15 2020-09-24 Modernatx, Inc. Hiv rna vaccines
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
CN112233741B (en) * 2020-09-30 2024-03-01 吾征智能技术(北京)有限公司 Text classification system, equipment and storage medium based on clustering

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BALDI, A. ET AL.: "Differential expression of the retinoblastoma gene family members pRb/p105, p107, and pRb2/p130 in lung cancer.", CLINICAL CANCER RESEARCH, vol. 2, July 1996 (1996-07-01), pages 1239 - 45, XP002099965 *
CARMECI, C. ET AL.: "Identification of a gene (GPR30) with homolgy to the G-protein-coupled receptor superfamily associated with estrogen receptor expression in breast cancer.", GENOMICS, vol. 45, no. 3, 1 November 1997 (1997-11-01), pages 607 - 17, XP002099963 *
NUCLEIC ACID RESEARCH, vol. 23, no. 19, 1995, pages 4007 - 8, XP002099962 *
RADINSKY, R. ET AL.: "Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells.", CLINICAL CANCER RESEARCH, vol. 1, January 1995 (1995-01-01), pages 19 - 31, XP002099964 *
YEATMAN, T.J. ET AL.: "Identification of genetic alterations associated with the process of human experimental colon cancer liver metastasis in the nude mouse.", CLINICAL AND EXPERIMENTAL METASTASIS, vol. 14, no. 3, May 1996 (1996-05-01), pages 246 - 252, XP002099961 *

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9447164B2 (en) 2010-08-06 2016-09-20 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9334328B2 (en) 2010-10-01 2016-05-10 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US9533047B2 (en) 2011-03-31 2017-01-03 Modernatx, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9428535B2 (en) 2011-10-03 2016-08-30 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US9271996B2 (en) 2011-12-16 2016-03-01 Moderna Therapeutics, Inc. Formulation and delivery of PLGA microspheres
US9186372B2 (en) 2011-12-16 2015-11-17 Moderna Therapeutics, Inc. Split dose administration
US9295689B2 (en) 2011-12-16 2016-03-29 Moderna Therapeutics, Inc. Formulation and delivery of PLGA microspheres
US9192651B2 (en) 2012-04-02 2015-11-24 Moderna Therapeutics, Inc. Modified polynucleotides for the production of secreted proteins
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9220792B2 (en) 2012-04-02 2015-12-29 Moderna Therapeutics, Inc. Modified polynucleotides encoding aquaporin-5
US9233141B2 (en) 2012-04-02 2016-01-12 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with blood and lymphatic disorders
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9221891B2 (en) 2012-04-02 2015-12-29 Moderna Therapeutics, Inc. In vivo production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9216205B2 (en) 2012-04-02 2015-12-22 Moderna Therapeutics, Inc. Modified polynucleotides encoding granulysin
US9301993B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides encoding apoptosis inducing factor 1
US9220755B2 (en) 2012-04-02 2015-12-29 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with blood and lymphatic disorders
US8999380B2 (en) 2012-04-02 2015-04-07 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
US9149506B2 (en) 2012-04-02 2015-10-06 Moderna Therapeutics, Inc. Modified polynucleotides encoding septin-4
US9114113B2 (en) 2012-04-02 2015-08-25 Moderna Therapeutics, Inc. Modified polynucleotides encoding citeD4
US9107886B2 (en) 2012-04-02 2015-08-18 Moderna Therapeutics, Inc. Modified polynucleotides encoding basic helix-loop-helix family member E41
US9095552B2 (en) 2012-04-02 2015-08-04 Moderna Therapeutics, Inc. Modified polynucleotides encoding copper metabolism (MURR1) domain containing 1
US9675668B2 (en) 2012-04-02 2017-06-13 Moderna Therapeutics, Inc. Modified polynucleotides encoding hepatitis A virus cellular receptor 2
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA

Also Published As

Publication number Publication date
EP1190058A2 (en) 2002-03-27
WO1999033982A2 (en) 1999-07-08
JP2002500010A (en) 2002-01-08
AU2095599A (en) 1999-07-19

Similar Documents

Publication Publication Date Title
WO1999033982A3 (en) Human genes and gene expression products i
WO1999038972A3 (en) Human genes and gene expression products ii
WO1999058675A3 (en) Human genes and gene expression products v
WO2002014500A3 (en) Human genes and gene expression products
WO2001066753A3 (en) Human genes and gene expression products
EP1005540A4 (en) Ikk-beta proteins, nucleic acids and methods
WO2000040614A3 (en) Characterization of the soc/crac calcium channel protein family
MXPA02011656A (en) Nrg 2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods.
WO1999053061A3 (en) Tumor associated nucleic acids and uses therefor
WO1999064594A8 (en) Genes and gene expression products that are differentially regulated in prostate cancer
WO2001005825A3 (en) Nucleic acid sequences encoding putative angiopoietin proteins
WO2002044320A3 (en) Human elongase genes and uses thereof
WO2001012776A3 (en) 18 human secreted proteins
WO2000077026A8 (en) 49 human secreted proteins
WO2000077239A3 (en) Novel genes encoding proteins having diagnostic, preventive, therapeutic, and other uses
WO2000073323A3 (en) Adam polynucleotides and polypeptides
WO2000018916A3 (en) Human genes and gene expression products
WO2000063230A3 (en) 49 human secreted proteins
WO2001072781A3 (en) Human genes and expression products
WO2001064876A3 (en) Human schizophrenia gene
WO2000061774A3 (en) Bone morphogenic proteins
WO2001012775A8 (en) 25 human secreted proteins
WO2000058339A3 (en) 50 human secreted proteins
WO2001014415A3 (en) Egfh2 genes and gene products
WO2000043495A3 (en) 33 human secreted proteins

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 526638

Kind code of ref document: A

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 1998965500

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 1998965500

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1998965500

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载